Navigation Links
Replidyne Discontinues Phase III Trial
Date:4/23/2008

st-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile- associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-K filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are avail
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Replidyne Provides Strategic Update
2. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
3. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
4. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
5. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
6. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
7. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
8. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
9. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
10. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
11. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (NYSE: RMD ), a pioneer and innovator in ... sleep apnea solutions specifically for women, is launching a new ... night,s sleep. The Better Sleep For Women ... just part of living a busy life. It will encourage ... health, essential to not only living an active lifestyle but ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems ... will report results for the fourth quarter of fiscal ... Wednesday, October 22, 2014.  The news release will be ... at 2:00 p.m. PT.  The news release and a ... on the company website at: www.varian.com/investor .  To ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal ... PHIA) today announced its eCareCoordinator and eCareCompanion telehealth ... Food and Drug Administration (FDA). A part of ... programs , eCareCoordinator and eCareCompanion are focused on ... first clinical applications to be available through the ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4
... Jan. 11, 2011 Reportlinker.com announces that a ... catalogue: Novo Nordisk A/S: PharmaVitae ... Introduction This ... Novo Nordisk in the prescription pharmaceutical sector. The ...
... 11, 2011 Reportlinker.com announces that ... available in its catalogue: ... New pricing rules set to negatively ... internationally http://www.reportlinker.com/p0360217/Germany-Pharmaceutical-Market-Overview-–-New-pricing-rules-set-to-negatively-impact-drug-sales-both-domestically-and-internationally.html ...
Cached Medicine Technology:Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile 2Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally 2
(Date:10/1/2014)... beta-amyloid is strongly associated with Alzheimer,s disease; however, researchers ... is the causal agent of the onset and development ... is that beta-amyloid is not harmful when found in ... it self-assembles to form the so-called amyloid fibrils , ... alone, but with multiple ones because each aggregate of ...
(Date:10/1/2014)... by the Engineering and Physical Sciences Research Council ... UK,s vital industrial control systems which run, for ... and the rail network. , The research ... or malware infiltrating the systems behind our critical ... Trustworthy Industrial Control Systems (RITICS), based at Imperial ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post ... , Senior citizens can qualify for affordable term ... seniors who are over 50 years old. Some term ... medical examination. , Term life insurance with a simplified ... qualify. Having life insurance during retirement is important for ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... new study shows men with prostate cancer who receive a ... reduce // the risk of recurrence after surgery may be ... showed men treated with androgen deprivation therapy (ADT) after prostate ... most common among women. Men who are older, smoke, or ...
... with the oral drug bosentan (Tracleer) has led to ... hypertension ( PAH) // . ,PAH is usually ... believed to cause the overproduction of endothelin, which increases ... This chronic obstruction leads to PAH, a condition that ...
... intense course of radiation after a lumpectomy may be ... on findings of a recent study. Standard treatment for ... weeks of radiation daily after undergoing surgery , however ... treatment is a major inconvenience leading them to choose ...
... a urinary tract infection can increase your chances of having ... few days, say researchers based on findings of a recent ... anytime we have an infection, to atherosclerosis, or clogging of ... of infections, some have speculated they, too, could aggravate the ...
... the existing drugs on the market are losing their ... bacteria hence researchers feel that the ocean is a ... ,More than 1 million microorganisms fill every milliliter of ... for some of our deadliest diseases. Many marine organisms ...
... J. Rutter, a well known scientist and accomplished businessman ... patent applications,has announced intention to set up a high ... of "Hemogenomics", which will be a marketing, selling and ... the sidelines of the BioAsia 2004 conference Bangalore on ...
Cached Medicine News:
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Medicine Products: